Short answer: Vitamin C has an absorption ceiling that most prescribing conversations ignore. Uptake from the gut runs through a saturable sodium-dependent transporter (SVCT1), so once a patient is at steady state, plain oral doses above roughly 500 mg a day are largely excreted rather than absorbed — plasma plateaus around 70–80 µmol/L no matter how many more milligrams go in. That is why “just take more” stops working, and why clinicians in Kuala Lumpur and Singapore reach for intravenous infusions when they want higher exposure. A liposomal preparation is the middle path: by wrapping ascorbate inside a phospholipid vesicle, absorption is designed to bypass part of that saturable route. The published pharmacokinetic evidence is encouraging but variable — a 2025 scoping review found 9 of 10 trials reported higher exposure from liposomal vitamin C, with AUC increases ranging from about 1.3-fold to 7.2-fold depending on the formulation. That spread is the whole point for a prescriber: not all “liposomal” is the same, because how the vesicle is made determines what it does. Lynnity’s two core capabilities sit exactly here — liposomal supplement formulations built in-house with ultrasonic technology, and specialised creams in a skin-identical lipid base for topical ascorbate. Retail vitamin C is sold everywhere in Malaysia; a Lynnity compounded preparation is a different thing entirely, prepared only on a prescription from a registered doctor, under the Ministry of Health’s Good Compounding Practice (GCP) guideline.
Vitamin C is the supplement practitioners are least likely to think hard about, precisely because it is so familiar. It is cheap, it is everywhere, and patients self-prescribe it without being asked. That familiarity hides a formulation problem that is more interesting than almost anything else on the shelf, and a safety consideration that matters more in Malaysia than in most countries. This guide is written for prescribers and referring clinicians in KL, the Klang Valley and Singapore.
The absorption ceiling nobody mentions on the label
Ascorbate does not diffuse freely into the bloodstream. It is carried across the intestinal wall by SVCT1, a sodium-dependent transporter with high capacity but low affinity — and, critically, a finite ceiling. The pharmacokinetic consequences are well characterised and remarkably consistent across the literature.
Daily intakes up to roughly 200 mg are absorbed close to completely. Above that, the absorbed fraction falls progressively as the transporter saturates, with maximal saturation described in the region of 500–1,000 mg per oral dose. In patients already at steady state, doses above about 500 mg a day are excreted almost quantitatively. And the plasma plateau achievable by oral dosing sits at approximately 70–80 µmol/L — a hard ceiling that additional oral milligrams do not move.
Renal handling compounds the effect. The same transporter family mediates reabsorption in the kidney, and it is strongly dose-dependent: in a replete patient, very little of a surplus dose is retained. A patient taking 3,000 mg of standard ascorbic acid daily is, for the most part, producing expensive urine and, not infrequently, loose stools.
This is the practical background to a question clinics get constantly — why did the high-dose protocol not raise the level? The answer is usually not compliance. It is transporter physiology.
What liposomal delivery is designed to change
A liposome is a vesicle whose wall is a phospholipid bilayer, the same architecture as a cell membrane, enclosing a watery core. Ascorbate is water-soluble, so it sits in that aqueous interior, shielded from the gastric environment and presented to the intestinal wall inside a lipid package rather than as free ascorbate queuing for a saturated transporter.
The evidence base has matured considerably. Randomised crossover work has reported meaningful increases in area under the curve for liposomal versus non-liposomal ascorbate — one powder formulation showed roughly a 30% AUC increase with elevated levels sustained longer at 24 hours; another stabilised formulation reported a 7.62-fold bioavailability advantage and a 6.29-fold higher Cmax. A double-blind placebo-controlled trial found liposomal delivery raised vitamin C in both plasma and leukocytes, which is arguably the more interesting endpoint. Pooling this, the 2025 scoping review’s finding of 9 of 10 studies favouring liposomal delivery, at 1.3- to 7.2-fold higher AUC, is a fair summary of where the field sits.
Two honest caveats belong alongside those numbers. The variation between formulations is enormous, and it tracks the quality of the liposome rather than the milligrams on the label. And higher plasma exposure is a pharmacokinetic outcome, not a clinical one — better absorption is not itself a treatment for anything, and nothing here should be read as a claim that it is.
Why how the vesicle is made decides what it does
This is where a compounded preparation and a bottle marked “liposomal” part company. Vesicle size and uniformity determine whether a liposome behaves as intended or simply disperses.
Lynnity builds its liposomes with ultrasonic technology. High-frequency sound waves create and collapse microscopic cavities throughout the lipid dispersion, and those micro-implosions shear the lipid into small, uniform vesicles. The energy density involved is well beyond what mechanical mixing reaches — not stirred, not homogenised in the ordinary sense, but cavitation. The process is designed to yield a consistent, reproducible vesicle population batch to batch. We describe what the technology does; we do not attach an absorption multiple or a health outcome to it.
The safety points that stay with the prescriber
High-dose vitamin C is treated casually by the public and should not be by clinicians. Four considerations recur, and the first is disproportionately relevant in this region.
G6PD deficiency
Malaysia screens every newborn for glucose-6-phosphate dehydrogenase deficiency by heel-prick, and has done since the 1980s, because prevalence here is high — published figures put male prevalence at roughly 4.6% in Malays, 6.0% in Chinese and 1.3% in Indians, with substantially higher rates reported in some Orang Asli communities. High-dose vitamin C generates hydrogen peroxide and other reactive oxygen species, which rapidly deplete the limited glutathione reserve of a G6PD-deficient red cell; case reports document haemolysis and methaemoglobinaemia following high-dose administration in deficient patients. Dose appears to be decisive — low-to-moderate doses are viewed very differently from gram-scale ones. For any Malaysian or Singaporean patient being considered for a high-dose regimen, G6PD status is a prescriber-level question that should be settled before, not after.
Renal function and oxalate
Ascorbate is metabolised in part to oxalate, so high chronic doses warrant caution in patients with a stone history or impaired renal function. Severe renal impairment is regarded as an absolute contraindication to high-dose intravenous protocols.
Iron loading
Vitamin C enhances non-haem iron absorption — useful when that is the intention, a consideration in haemochromatosis or iron overload when it is not.
Point-of-care glucose readings
High circulating ascorbate can interfere with some glucometer chemistries, which is worth flagging for diabetic patients on a high-dose regimen.
None of these is a reason to avoid vitamin C. They are reasons the preparation belongs on a prescription rather than in a shopping basket.
Where compounding changes the conversation
Retail ascorbate arrives in fixed strengths, in a manufacturer’s base, with a manufacturer’s excipient list. A prescription-led compounding pharmacy addresses each of those variables directly.
Dose granularity
Given the saturation curve, the useful clinical lever is often splitting a total daily dose rather than raising it — and the strength a prescriber wants for that frequently does not exist commercially. A compounded preparation is made to the specified strength, which makes real titration possible.
Buffered and gentler forms
Ascorbic acid is acidic and a common cause of gastrointestinal intolerance at higher doses. Buffered mineral ascorbates are better tolerated by many patients, and the choice of salt is a prescriber decision with its own mineral load implications.
The liposomal route
For prescribers who want exposure beyond what standard oral dosing achieves, without moving to infusion, a liposomal preparation built to a defined specification is the direct answer to the transporter ceiling described above.
Combination in one preparation
Vitamin C is rarely prescribed alone. Where a clinician wants ascorbate alongside zinc, quercetin or another active in a single capsule, that consolidation is exactly what nutritional compounding does — reducing pill burden without the patient assembling it themselves.
Excipient control
Sugar-free, dye-free, allergen-conscious and excipient-minimal preparations are available where the patient’s history requires it.
Topical vitamin C in a specialised cream
Ascorbate is prominent in aesthetic and dermatology practice, where it is notoriously unstable and where the base determines whether anything reaches the skin at all. Specialised creams are Lynnity’s other core strength. Our skin-identical lipid base is built from the same lipid families the skin barrier is itself made of. Conventional penetration enhancers work by disrupting that lipid matrix to force passage, a common source of irritation; a skin-identical system is instead recognised by the barrier and integrates with its lamellar structure — not a solvent forcing entry, but a key the barrier already knows. Strength, form of ascorbate and base are set by the prescriber.
How a clinic works with us
Every Lynnity preparation, supplements included, is made only on a prescription from a registered doctor after assessment. There is no direct-purchase route. A clinic in KL, the Klang Valley or Singapore typically speaks with one of our pharmacists first to establish which forms, strengths, bases and beyond-use dates are achievable, then sends the prescription. Formulations are compounded under the Ministry of Health’s Good Compounding Practice (GCP) guideline.
Frequently asked questions
Is vitamin C not available over the counter in Malaysia?
Retail vitamin C supplements are sold widely, and nothing here changes that. A Lynnity compounded preparation is a different product: individualised in strength, form and excipient profile, and prepared only on a registered doctor’s prescription. There is no direct-purchase route for it.
Why does taking more standard vitamin C stop raising the level?
Absorption runs through the saturable SVCT1 transporter. Intakes up to roughly 200 mg a day are absorbed almost completely; above about 500 mg a day in a replete patient, most of the surplus is excreted, and oral dosing plateaus plasma at approximately 70–80 µmol/L.
Does liposomal vitamin C actually absorb better?
The published evidence generally supports it. A 2025 scoping review found 9 of 10 trials reported higher exposure, with AUC increases between about 1.3-fold and 7.2-fold. The range is wide because formulation quality varies enormously, and higher absorption is a pharmacokinetic finding, not a clinical claim.
Should we screen for G6PD deficiency before a high-dose regimen?
G6PD status is a prescriber-level question and a particularly relevant one in Malaysia, where newborn screening is routine because prevalence is high. High-dose vitamin C has been reported to precipitate haemolysis in deficient patients, and dose appears decisive. That assessment belongs with the prescribing doctor before a regimen starts.
Where does an oral liposomal preparation sit relative to an infusion?
They answer different questions. Intravenous administration bypasses intestinal absorption entirely and reaches concentrations oral dosing cannot. A liposomal oral preparation is designed to improve on standard oral absorption while remaining an oral preparation. Which is appropriate is a clinical decision for the prescriber, not a formulation one.
Can Lynnity prepare a liposomal vitamin C?
Yes. Liposomal supplement formulation is one of our two core capabilities, and the liposomes are built in-house with ultrasonic technology — sound waves shear the lipid into small, uniform vesicles rather than mixing them mechanically. Strength and form follow the prescription, and no absorption or outcome promise is attached.
Can it be combined with other actives in one capsule?
Often, yes. Ascorbate with zinc, quercetin or other actives in a single made-to-prescription capsule is routine nutritional compounding, subject to compatibility and stability assessment by our pharmacists.
Can you compound topical vitamin C?
Yes. Specialised creams are our other core capability. A topical ascorbate preparation is made in our skin-identical lipid base, built from the lipid families the skin barrier is made of, so it integrates with the barrier rather than disrupting it. The form of ascorbate, strength and base are set by the prescriber.
We run a clinic in KL or Singapore — how do we start?
Contact us through lynnitypharma.com and ask to speak with a pharmacist. We can talk through achievable forms, strengths, liposomal specifications, cream bases and beyond-use dating before your first prescription is sent.
Reviewed by the Lynnity pharmacy team — registered pharmacists compounding to Good Compounding Practice (GCP) in Kuala Lumpur.
This article is general information for healthcare practitioners and is not medical advice. It does not diagnose, treat or recommend therapy for any condition. Compounded vitamin C preparations at Lynnity are prepared only on a prescription from a registered doctor.